Relative Bioavailability Study of HNC364 Injectable Suspension
NCT06798519
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson's Disease (PD)
Interventions
DRUG:
HNC364 Injectable Suspension
DRUG:
Rasagiline Tablets
Sponsor
Guangzhou Henovcom Bioscience Co. Ltd.
Collaborators
[object Object]